{'fraction_non_alphanumeric': 0.03341687552213868, 'fraction_numerical': 0.018379281537176273, 'mean_word_length': 5.730337078651686, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles

Abstract Chitosan-coated ISCOMATRIX nanoparticles co-administrated with PR8 influenza virus were successfully developed via a lipid film hydration method to evaluate their in vivo immuniadjuvant potential in immunization against influenza. The prepared ISCOMATRIX (ISC) and chitosan-coated ISCOMATRIX (ISC-CIT) showed a particle size of 171 and 233 nm with a zeta potential of –9.47 and +5.65, respectively. Furthermore, ISC-CIT formulations were co-administered with PR8 antigen (PR8-ISC-CIT) and their immunogenicity was investigated after intranasal and intramuscular immunization of BALBc/mice. The PR8-ISC formulation elicited more IFN-γ after intranasal or intramuscular administration compared with PR8-ISC-CIT formulation. In contrast, although PR8-ISC-CIT formulation administered by intranasal route secreted more IFN-γ, it significantly decreased the IgG2a/IgG1 ratio and a less immune response was induced. Altogether, the ISC-adjuvanted influenza PR8 antigen could be considered as a powerful intramuscular antigen delivery system for producing a variety of prophylactic and therapeutic vaccines.